Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nordea and Swedbank in connection with K2A’s establishment of its MTN programme
Mandate

Vinge advises Nordea and Swedbank in connection with K2A’s establishment of its MTN programme

May 21, 2021 Banking and Finance

Vinge has advised Nordea Bank Abp and Swedbank AB (publ) as lead arrangers and issuing agents in connection with the structuring, documenting and establishment of K2A Knaust & Andersson Fastigheter AB (publ) (”K2A”) unsecured medium term note programme (the “MTN Programme”). The MTN Programme is part of K2A’s debt financing and allows K2A to issue senior unsecured medium term notes in an aggregate amount of up to SEK 3,000,000,000 in SEK or EUR, with a minimum tenor of one year.

In contrast to customary MTN programmes, the MTN Programme was structured to be aligned with the terms and structure of high yield bonds issued on a standalone basis – making the MTN Programme one of the first of its kind in Sweden.

K2A has prepared a base prospectus which has been approved by, and registered with, the Swedish Financial Supervisory Authority.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda and Felix Möller.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026